BOSTON & WHITEHOUSE STATION, N.J.--()--MassBiologics (MBL) of the University of Massachusetts Medical School and Merck & Co., Inc. (NYSE: MRK) announced today that they have entered into an agreement that provides Merck with exclusive rights to market and distribute MBL's tetanus and diphtheria toxoids adsorbed (Td) vaccine in the United States, with the exception of Massachusetts, where MBL will continue distributing the vaccine. Merck plans to begin distributing the Td vaccine in June 2010. Specific financial details of the agreement were not disclosed.
“Adult vaccination is an important element in Merck's commitment to help people be well, and we are delighted to partner with MBL to add tetanus-diphtheria vaccine to our broad U.S. portfolio of adult vaccines”
"Adult vaccination is an important element in Merck's commitment to help people be well, and we are delighted to partner with MBL to add tetanus-diphtheria vaccine to our broad U.S. portfolio of adult vaccines," said Soren Bo Christiansen, M.D., senior vice president and general manager, Adolescent & Adult Vaccines, Merck Vaccines. "This agreement is another example of how Merck engages in partnerships that will enable us to bring the most robust portfolio of products to our customers."
MassBiologics' Td vaccine was licensed by the U.S. Food and Drug Administration (FDA) in 1970. The vaccine is indicated for active immunization for the prevention of tetanus and diphtheria and is approved for use in people seven years of age and older.
The U.S. Centers for Disease Control and Prevention (CDC) recommends that adults 19 years of age and older with an uncertain or incomplete history of receiving the primary vaccination series of three doses of Td vaccine should begin or complete the Td primary vaccination series, and that adults who have not had a Td booster shot in 10 years or more should be vaccinated. Adults 19 years of age and older should receive a booster dose of Td vaccine every 10 years. Tdap (tetanus, diphtheria, and acellular pertussis) vaccine should replace a single dose of Td for adults aged 19–64 years who have not received a dose of Tdap previously, to additionally help protect them against pertussis disease.
Tetanus and diphtheria can be serious diseases
Cases of tetanus and diphtheria have been drastically reduced in the U.S. since the introduction of vaccines, but people can still be at risk for these diseases. The bacteria that cause tetanus are found in soil and can enter the body through any cut or wound. Tetanus is not spread from person to person. Because tetanus bacteria are widespread in the environment, vaccination is an important way to protect against tetanus. Almost all cases of tetanus occur in people who have never been vaccinated or who have not had a tetanus booster shot within the preceding 10 years.
Tetanus, sometimes called "lockjaw," is a bacterial infection affecting the nervous system. It causes severe muscle spasms that can lead to, among other things, "locking" of the jaw so a person cannot open his/her mouth or swallow. Symptoms include stiffness in the neck, rigidity of abdominal muscles, difficulty with breathing and swallowing, and muscle spasms can cause fractures of the spine and long bones. According to the CDC, approximately 1 out of 5 cases of tetanus are fatal.
Diphtheria is rare in the U.S. due to widespread use of diphtheria-containing vaccines; however, these bacteria are still a concern. Diphtheria continues to occur in other parts of the world. Diphtheria is caused by bacteria that can be passed from an infected person to others by coughing or sneezing. Early symptoms of diphtheria include sore throat, mild fever and chills. Usually the disease causes a thick coating at the back of the throat that makes it difficult to breathe or swallow, and may cause serious breathing problems. The most common complications are inflammation of the heart that can lead to abnormal heart rhythms, and inflammation of the nerves, which can cause temporary paralysis of some muscles. Diphtheria bacteria not only affects the throat, but can also infect other areas of the body, such as the nose, eye, and skin.
Important information about tetanus-diphtheria vaccine
The tetanus diphtheria vaccine is contraindicated in patients with hypersensitivity to any component of the vaccine or who have had a severe allergic reaction after a previous dose of this vaccine or any other Td vaccine.
Persons who experienced an Arthus-type hypersensitivity reaction following a prior dose of a tetanus toxoid-containing vaccine usually have high serum tetanus antitoxin levels and should not receive the Td vaccine more frequently than every 10 years, even for tetanus prophylaxis as part of wound management.
If Guillain-Barre Syndrome occurred within six weeks after receipt of a previous dose of tetanus toxoid-containing vaccine, the decision to give subsequent doses of the Td vaccine or any vaccine containing tetanus toxoid should be based on careful consideration of the potential benefits and possible risks.
The most common local adverse reactions associated with Td vaccine may include erythema (redness), tenderness, and swelling at the injection site. Common systemic reactions may include headache, malaise, and temperature elevations.
Please see the accompanying Prescribing Information for Td vaccine.
MassBiologics is the only non-profit FDA-licensed manufacturer of vaccines and other biologic products in the United States and produces tetanus-diphtheria vaccine. MassBiologics traces its roots to 1894, and since then has maintained a mission to improve public health through applied research, development and production of biologic products. MassBiologics has been a part of the University of Massachusetts Medical School since 1997.
About the University of Massachusetts Medical School
The University of Massachusetts Medical School, one of the fastest growing academic health centers in the country, has built a reputation as a world-class research institution, consistently producing noteworthy advances in clinical and basic research. The Medical School attracts more than $240 million in research funding annually, 80 percent of which comes from federal funding sources. The mission of the Medical School is to advance the health and well-being of the people of the commonwealth and the world through pioneering education, research, public service and health care delivery with its clinical partner, UMass Memorial Health Care. For more information, visit www.umassmed.edu.
Today's Merck is a global healthcare leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. Merck. Be well. For more information, visit www.merck.com.
This news release includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such statements may include, but are not limited to, statements about the benefits of the merger between Merck and Schering-Plough, including future financial and operating results, the combined company’s plans, objectives, expectations and intentions and other statements that are not historical facts. Such statements are based upon the current beliefs and expectations of Merck’s management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements.
The following factors, among others, could cause actual results to differ from those set forth in the forward-looking statements: the possibility that the expected synergies from the merger of Merck and Schering-Plough will not be realized, or will not be realized within the expected time period, due to, among other things, the impact of pharmaceutical industry regulation and pending legislation that could affect the pharmaceutical industry; the risk that the businesses will not be integrated successfully; disruption from the merger making it more difficult to maintain business and operational relationships; Merck’s ability to accurately predict future market conditions; dependence on the effectiveness of Merck’s patents and other protections for innovative products; the risk of new and changing regulation and health policies in the U.S. and internationally and the exposure to litigation and/or regulatory actions.
Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in Merck’s 2009 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).
Prescribing Information for tetanus-diphtheria vaccine is attached.
TETANUS AND DIPHTHERIA TOXOIDS ADSORBED
Tetanus and Diphtheria Toxoids Adsorbed (Td) manufactured by MassBiologics is a sterile vaccine for intramuscular injection. After shaking, the vaccine appears as a homogeneous milky white suspension.
Each 0.5 ml dose of MassBiologics’ Td is formulated to contain the following active ingredients: 2 Lf of tetanus toxoid and 2 Lf of diphtheria toxoid. Each 0.5 ml dose also contains aluminum adjuvant (not more than 0.53 mg aluminum by assay), < 100 mcg (0.02%) of residual formaldehyde, and a trace amount of thimerosal [mercury derivative, (≤ 0.3 mcg mercury/dose)] (not as a preservative) from the manufacturing process.
The Corynebacterium diphtheriae and Clostridium tetani organisms are grown on modified Mueller's media1, 2 which contains bovine extracts. The bovine material used in these extracts is sourced from countries which the United States Department of Agriculture has determined neither have nor present an undue risk for bovine spongiform encephalopathy. Tetanus and diphtheria toxins produced during growth of the cultures are detoxified with formaldehyde. The detoxified materials are then separately purified by ammonium sulfate fractionation. The diphtheria toxoid is further purified by column chromatography. The tetanus and diphtheria toxoids are individually adsorbed onto aluminum phosphate.
The tetanus and diphtheria toxoids induce at least 2 units and 1 unit of antitoxin per ml of serum, respectively, in the guinea pig potency test.
Tetanus (also known as lockjaw) is a serious, often fatal disease caused by an extremely potent neurotoxin produced by C. tetani.
Protection against disease is due to the development of neutralizing antibodies to tetanus toxin. A serum tetanus antitoxin level of 0.01 IU/ml measured via a neutralization assay is considered the minimum protective level.3, 4 The efficacy against tetanus of MassBiologics’ Td is supported by the following:
Diphtheria is an acute toxin-mediated disease caused by toxigenic strains of C. diphtheriae. Protection against disease is due to the development of neutralizing antibodies to diphtheria toxin. A serum diphtheria antitoxin level of 0.01 IU/ml is the lowest level giving some degree of protection.3, 6 The efficacy against diphtheria of MassBiologics’ Td is supported by the following:
INDICATIONS AND USAGE
MassBiologics’ Td is a vaccine indicated for active immunization for the prevention of tetanus and diphtheria. This vaccine is approved for use in persons 7 years of age and older.
A severe allergic reaction (e.g., anaphylaxis) occurring after a previous dose of this vaccine, or any other tetanus or diphtheria toxoid-containing vaccine, or any component of this vaccine is a contraindication to administration of MassBiologics’ Td vaccine. (See DESCRIPTION). Because of the uncertainty as to which component of the vaccine might be responsible, no further vaccination with diphtheria or tetanus components should be carried out. Alternatively, such individuals may be referred to an allergist for evaluation if further immunizations are to be considered.
FREQUENCY OF ADMINISTRATION
More frequent administration of MassBiologics’ Td than described in DOSAGE AND ADMINISTRATION may be associated with an increased incidence and severity of adverse reactions.
Persons who experienced an Arthus-type hypersensitivity reaction following a prior dose of a tetanus toxoid-containing vaccine usually have high serum tetanus antitoxin levels and should not receive MassBiologics’ Td more frequently than every 10 years, even for tetanus prophylaxis as part of wound management. (See DOSAGE AND ADMINISTRATION).
A review by the Institute of Medicine found evidence for a causal relation between tetanus toxoid and Guillain-Barré Syndrome.9 If Guillain-Barré Syndrome occurred within 6 weeks after receipt of a previous dose of tetanus toxoid-containing vaccine, the decision to give subsequent doses of MassBiologics’ Td or any vaccine containing tetanus toxoid should be based on careful consideration of the potential benefits and possible risks. 10
Vaccination with MassBiologics’ Td may not protect all individuals.
Epinephrine injection (1:1000) and other appropriate agents and equipment must be immediately available should an acute anaphylactic reaction occur.
Prior to the administration of MassBiologics’ Td, the vaccine recipient’s current health status and health history should be reviewed. This includes a review of the immunization history of the patient, the presence of any contraindications to immunization, and any adverse events after previous immunizations to allow an assessment of the benefits and risks of vaccination. (See CONTRAINDICATIONS and WARNINGS).
If MassBiologics’ Td is administered to immunocompromised persons (whether from disease or treatment) the expected immune response may not be obtained.
INFORMATION FOR PATIENTS
Prior to administration of MassBiologics’ Td, patients, parents or guardians should be informed by the health care provider of the benefits and risks of immunization with Td and of the importance of completing the primary immunization series or receiving recommended booster doses.
The health care provider should inform the patient, parent, or guardian of the potential for adverse reactions that have been temporally associated with MassBiologics’ Td or other vaccines containing similar ingredients. Patients, parents or guardians should be instructed to report any suspected adverse reactions to their health care provider.
According to the National Childhood Vaccine Injury Act of 1986, Vaccine Information Statements must be provided by the health care provider with each vaccine dose administered.10
Patients who are on immunosuppressive therapy, including alkylating agents, antimetabolites, cytotoxic drugs, irradiation, or corticosteroids (used in greater than physiologic doses), may have a reduced immune response to vaccines.
No safety and immunogenicity data are available on the concomitant administration of MassBiologics’ Td vaccine with other U.S. licensed vaccines.
CARCINOGENESIS, MUTAGENESIS, IMPAIRMENT OF FERTILITY
No studies have been performed with MassBiologics’ Td to evaluate carcinogenicity, mutagenic potential, or impairment of fertility.
PREGNANCY CATEGORY C
Animal reproduction studies have not been conducted with MassBiologics’ Td. It is also not known whether MassBiologics’ Td can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. MassBiologics’ Td should be given to a pregnant woman only if clearly needed.
It is not known whether MassBiologics’ Td is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when MassBiologics’ Td is administered to a nursing woman.
MassBiologics’ Td is not approved for use in infants and children younger than 7 years of age. The safety and effectiveness of MassBiologics’ Td in this age group have not been established.
No studies have been performed with MassBiologics’ Td in adults aged 65 years and older in order to determine whether they respond differently than younger subjects.
DATA FROM CLINICAL TRIALS
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a vaccine cannot be directly compared to rates in the clinical trials of another vaccine, and may not reflect the rates observed in practice. However, the adverse reaction information from clinical trials provides a basis for identifying adverse events that appear to be related to vaccine use and for approximating rates. Data on adverse reactions following fluid and adsorbed preparations of MassBiologics’ Td with various doses of the diphtheria and tetanus components have been reported in a series of studies.5, 7, 8, 11, 12
The following adverse events have been identified during post-approval use of MassBiologics’ Td. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequencies or to establish a causal relationship to vaccination. The following adverse events were included because of seriousness or frequency of reporting:
General Disorders and Administration Site Conditions: Injection site reactions, including pain, tenderness, erythema, induration, pruritis, swelling and warmth; peripheral oedema, pyrexia, malaise
Nervous System Disorders: Dizziness, headache, convulsions
Musculoskeletal and Connective Tissue Disorders: Myalgia, musculoskeletal stiffness or pain, arthralgia
Skin and Subcutaneous Tissue Disorders: Rash
Gastrointestinal Disorders: Nausea
Infections and Infestations: Cellulitis
REPORTING OF SUSPECTED ADVERSE REACTIONS
To report SUSPECTED ADVERSE REACTIONS, contact MassBiologics at 1-800-457-4626 or VAERS at 1-800-822-7967 or www.vaers.hhs.gov.
DOSAGE AND ADMINISTRATION
MassBiologics’ Td may be used in persons 7 years of age and older who have not been previously immunized against tetanus and diphtheria, as a primary immunization series consisting of three 0.5 ml doses. The first two doses are administered 4-8 weeks apart and the third dose is administered 6-12 months after the second dose.
MassBiologics’ Td may be used to complete the primary immunization series for tetanus and diphtheria, following one or two doses of Diphtheria and Tetanus Toxoids and Pertussis Vaccine Adsorbed (whole-cell DTP), Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed (DTaP) and/or Diphtheria and Tetanus Toxoids Adsorbed (DT) vaccine. However, the safety and efficacy of MassBiologics’ Td in such regimens have not been evaluated.
ROUTINE BOOSTER IMMUNIZATION
MassBiologics’ Td may be used for routine booster immunization against tetanus and diphtheria in persons 7 years of age and older who have completed primary immunization against tetanus and diphtheria. Routine booster immunization against tetanus and diphtheria is recommended in children 11-12 years of age and every 10 years thereafter.10
The Advisory Committee on Immunization Practices (ACIP) has specific recommendations on booster immunization against tetanus and diphtheria for adolescents and adults.10, 13, 14
TETANUS PROPHYLAXIS IN WOUND MANAGEMENT
For active tetanus immunization in wound management of patients 7 years of age and older, a preparation containing tetanus and diphtheria toxoids is preferred instead of single-antigen tetanus toxoid to enhance diphtheria protection.15 MassBiologics’ Td is approved for wound management of patients 7 years of age and older.
The need for active immunization with a tetanus toxoid-containing preparation, with or without Tetanus Immune Globulin (TIG) (Human) depends on both the condition of the wound and the patient’s vaccination history (Table 1).
When indicated, TIG (Human) should be administered using a separate needle and syringe at a different anatomic site, according to the manufacturer’s package insert. If a contraindication to using a tetanus toxoid-containing vaccine exists in a person who has not completed tetanus primary immunization and other than a clean, minor wound is sustained, only passive immunization with TIG (Human) should be given.15
TABLE 1 GUIDE TO TETANUS PROPHYLAXIS IN ROUTINE WOUND MANAGEMENT IN PERSONS AGED 7 YEARS AND OLDER13, 14, 15
|History of Adsorbed Tetanus Toxoid (Doses)||Clean, Minor Wounds||All Other Wounds*|
|Unknown or < 3||Yes||No||Yes||Yes|
|≥ 3 ‡||No§||No||No¶||No|
* Such as, but not limited to, wounds contaminated with dirt, feces, soil, and saliva; puncture wounds; avulsions; and wounds resulting from missiles, crushing, burns and frostbite.
† The ACIP has specific recommendations on use of Td or Tetanus Toxoid, Reduced Diphtheria Toxoids and Acellular Pertussis Vaccine Adsorbed (Tdap) in adolescents and adults.13, 14
‡ If only three doses of fluid tetanus toxoid have been received, then a fourth dose of toxoid, preferably an adsorbed toxoid, should be given.
§ Yes, if ≥ 10 years since the last tetanus toxoid-containing vaccine dose.
¶ Yes, if ≥ 5 years since the last tetanus toxoid-containing vaccine dose. (More frequent boosters are not needed and can accentuate side effects.)
DIPHTHERIA PROPHYLAXIS FOR CASE CONTACTS
MassBiologics’ Td may be used for post-exposure diphtheria prophylaxis in persons 7 years of age and older who have not completed primary vaccination, whose vaccination status is unknown, or who have not been vaccinated with diphtheria toxoid within the previous 5 years. Consult ACIP recommendations for additional interventions for post-exposure diphtheria prophylaxis.15
Shake the vial well to resuspend the vaccine before withdrawing the dose. After shaking, MassBiologics’ Td is a homogenous milky white suspension. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. If these conditions exist, MassBiologics’ Td should not be administered.
Inject 0.5 ml of MassBiologics’ Td intramuscularly. The preferred site is the deltoid muscle. The vaccine should not be injected into the gluteal area or areas where there may be a major nerve trunk.
Do not administer this vaccine intravenously, subcutaneously, or intradermally.
MassBiologics’ Td should not be combined through reconstitution or mixed with any other vaccine.
The stopper of the vial is latex free.
MassBiologics’ Td is supplied in single-dose (0.5 ml) vials.
NDC No. 14362-0111-3 – Package of 10 single dose vials.
Store at 2°C - 8°C (36°F - 46°F). DO NOT FREEZE. Discard product if exposed to freezing.
Do not use vaccine after expiration date.
|University of Massachusetts Medical School|
|Boston, MA 02130|
|US Government License No. 1779|
Product information as of April 2009